One biomarker implicated in PCa progression and drug resistance is High Mobility Group AT Hook-2 (HMGA2), which is associated with aggressive phenotypes and resistance to therapy [5,6,7,8]. Here, HMGA2 is linked to posterior cortical atrophy.